EP1926484A2 - Depigmenting composition for the skin, comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent - Google Patents

Depigmenting composition for the skin, comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent

Info

Publication number
EP1926484A2
EP1926484A2 EP06842260A EP06842260A EP1926484A2 EP 1926484 A2 EP1926484 A2 EP 1926484A2 EP 06842260 A EP06842260 A EP 06842260A EP 06842260 A EP06842260 A EP 06842260A EP 1926484 A2 EP1926484 A2 EP 1926484A2
Authority
EP
European Patent Office
Prior art keywords
depigmenting
adapalene
agent
skin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06842260A
Other languages
German (de)
French (fr)
Inventor
Isabelle Pelisson
André Jomard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0509003A external-priority patent/FR2890314B1/en
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Publication of EP1926484A2 publication Critical patent/EP1926484A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • the invention relates to a depigmenting composition for the skin, comprising, in a physiologically acceptable medium, adapalene (6- [3- (1-adamantyl) -4-methoxyphenyl] - 2-naphthanoic acid) , at least one depigmenting agent and at least one anti-inflammatory agent, and to its pharmaceutical or cosmetic use.
  • adapalene 6- [3- (1-adamantyl) -4-methoxyphenyl] - 2-naphthanoic acid
  • A.M. Kligman describes, in US Patent 3,856,934, a depigmenting composition comprising hydroquinone, reti- noic acid and a corticosteroid. This type of combination allows good depigmentation of the skin but causes substantial adverse effects such as irritation and itching.
  • Retinoic acid is known to have, on its own, a skin depigmenting activity (Guevara I.A. and Pandya A. G. Int. J. Dermatol. 40, 210-215 (2001)).
  • tretinoin used at 0.01% or 0.03%, induces depigmentation of the tail which begins from the first week of treatment and progresses to reach a clear depigmentation at 6 weeks.
  • the dose of 0.03% is capable of inhibiting the induction of pigmentation by UVB radiation, whereas the lower dose has no effect.
  • Tretinoin is therefore a depigmenting agent on its own.
  • adapalene has no depigmenting activity, as is shown in Example 5 hereinafter. Due to its lack of depigmenting activity in particular, nothing therefore encouraged those skilled in the art to combine it with a depigmenting agent in a depigmenting composition possibly containing an anti-inflammatory agent.
  • the Applicant has discovered, surprisingly, that the combination of adapalene, a depigmenting agent and an anti-inflammatory agent makes it possible to obtain a much more rapid depigmenting response than that obtained with the depigmenting agent alone.
  • the Applicant has also discovered, surprisingly, that good tolerance of the skin is obtained with the combination of adapalene, a depigmenting agent and an anti-inflammatory agent, at the same time keeping a considerable depigmenting activity.
  • the invention therefore relates to a depigmenting composition for the skin, comprising, in a physiologically acceptable medium, adapalene, at least one depigmenting agent distinct from adapalene, and at least one anti-inflammatory agent distinct from adapalene.
  • the composition according to the invention therefore comprises at least three different active ingredients .
  • physiologically acceptable medium is intended to mean a medium which is compatible with the skin, the mucous membranes and/or the integuments.
  • depigmenting agent is intended to mean any active agent having skin-depigmenting activity. This activity makes it possible to decrease the pigmentation of the skin that already exists and also to prevent any additional pigmentation above the natural pigmentation.
  • phenolic derivatives such as hydroquinone, hydroquinone monoethyl ether, hydro- quinone monobenzyl ether or 4-hydroxyanisole, kojic acid and its derivatives, azelaic acid and its derivatives, linoleic acid, resorcinol and its derivatives, ellagic acid, hydroxy acids such as glycolic acid, ascorbic acid, zinc peroxide, and mercury chloride.
  • the depigmenting composition for the skin may comprise, as depigmenting agent, a phenolic derivative, in particular hydroguinone .
  • the invention also relates to a depigmenting composition for the skin, comprising, in a physiologically acceptable medium, adapalene, at least one depigmenting agent distinct from adapalene and at least one anti-inflammatory agent distinct from adapalene.
  • the composition according to the invention advantageously comprises between 0.0001% and 20% by weight of adapalene relative to the total weight of the composition, and between 0.0001% and 20% by weight of depigmenting agent relative to the total weight of the composition, and preferably, respectively, between 0.001% and 10% by weight of adapalene relative to the total weight of the composition, and between 0.025% and 5% by weight of depigmenting agent relative to the total weight of the composition.
  • the composition comprises at least one steroidal or non-steroidal anti-inflammatory agent in preferential concentrations ranging from 0.001% to 20.00% by weight relative to the total weight of the composition.
  • steroidal anti-inflammatory agents mention may be made, by way of non-limiting example, of clobetasone butyrate, clobetasol propionate, clobetasol dipropio- nate, hydrocortisone, cortisone, prednisolone, miconazole, prednisone, triamcinolone acetonide, methyl- prednisolone, fluometholone, fluocinolone acetonide, desonide, betamethasone, dexamethasone, or mixtures thereof .
  • non-steroidal anti-inflammatory agents mention may be made, by way of non-limiting example, of indole derivatives, arylcarboxylic derivatives such as ibu- profen, oxicams, pyrazole compounds, salicylic acid and selective COX-2 inhibitors.
  • the depigmenting composition for the skin may comprise fluocinolone acetonide as antiinflammatory agent .
  • the composition may also comprise any additive normally used in the cosmetics or pharmaceutical field, such as sequestering agents, antioxidants, sunscreens, preserving agents, fillers, electrolytes, humectants, dyes, common inorganic or organic bases or acids, fragrances, essential oils, cosmetic active agents, moisturizers, vitamins, essential fatty acids, sphingolipids, self- tanning compounds, and skin calmative and protective agents such as allantoin.
  • any additive normally used in the cosmetics or pharmaceutical field such as sequestering agents, antioxidants, sunscreens, preserving agents, fillers, electrolytes, humectants, dyes, common inorganic or organic bases or acids, fragrances, essential oils, cosmetic active agents, moisturizers, vitamins, essential fatty acids, sphingolipids, self- tanning compounds, and skin calmative and protective agents such as allantoin.
  • any additive normally used in the cosmetics or pharmaceutical field such as sequestering agents, antioxidants, sunscreens, preserving agents, fillers, electrolytes,
  • additives may be present in the composition in a proportion of from 0.001% to 20% by weight relative to the total weight of the composition.
  • EDTA ethylenediaminetetraacetic acid
  • dihydroxyethylglycine citric acid and tartaric acid.
  • preserving agents mention may be made of benzalkonium chloride, phenoxyethanol , benzyl alcohol, diazolidinylurea and parabens .
  • humectants examples include: glycerol and sorbitol .
  • a subject of the present invention is also the composition according to the invention as described above, as a medicament.
  • the invention also relates to the use of the composition according to the invention as described above, in the pharmaceutical and cosmetics field.
  • compositions of the invention are particularly- suitable for the treatment and prevention of hyperpig- mentary disorders such as melasma, chloasma, lenti- gines, senile lentigo, freckles, post-inflammatory hyperpigmentations due to an abrasion, a burn, a scar, a dermatosis, a contact allergy; naevi, hyperpigmentations with genetic determinism, hyperpigmentations of metabolic or drug-related origin, melanomas or any other hyperpigmentary lesions .
  • hyperpig- mentary disorders such as melasma, chloasma, lenti- gines, senile lentigo, freckles, post-inflammatory hyperpigmentations due to an abrasion, a burn, a scar, a dermatosis, a contact allergy; naevi, hyperpigmentations with genetic determinism, hyperpigmentations of metabolic or drug-related origin,
  • compositions according to the invention also find application in the cosmetics field, in particular in protection against the harmful effects of the sun, for preventing and/or for combating photo-induced or chronological ageing of the skin and of the integuments .
  • This composition should be applied once a day until complete depigmentation is obtained, for the treatment of chloasma.
  • This composition should be applied twice a day until complete depigmentation is obtained, for the treatment of lentigines.
  • This composition should be- applied once a day until complete depigmentation is obtained, for the treatment of melasma.
  • This composition should be applied twice a day until complete depigmentation is obtained, for the treatment of lentigines.
  • Example 5 Measurement of the depigmenting activity of the combination of adapalene and a depigmenting agent
  • the evaluation of the depigmenting and/or anti-pigment- ing activity of 3% hydroquinone and of 0.1% adapalene, alone or in combination for 8 weeks, is carried out on the tail of an SKH:HR2 mouse irradiated with ultraviolet B radiation, or not irradiated.
  • the tail of the SKH-.HR2 mouse is naturally pigmented and this pigmentation increases under the effect of repeated UVB irradiation.
  • the depigmenting activity is measured on the natural pigmentation after application of the test product to the tail of non-irradiated animals.
  • the anti-pigmenting activity is measured by the inhibition of the induction of the UV-induced pigmentation: the test product is applied to the tail of UVB-irradiated animals .
  • the treatment is carried out 5 days a week for 8 weeks. 20 ⁇ l of test product diluted in acetone are applied to the tail with a gap between applications: the hydroquinone is applied in the morning and the adapalene 4 h later. On the days of irradiation, the treatment is applied after irradiation.
  • the animals are irradiated 3 times a week for 8 weeks (Monday, Wednesday, Friday) at the dose of 90 mJ/cm 2 of UVB.
  • the pigmentation is evaluated once a week before irradiation, by means of a score on a scale of 0 to 4.
  • the scores are divided up as follows:
  • Depigmentation scale scores -1 to -4.
  • Figure 1 represents the kinetics of the mouse tail skin pigmentation scores as a function of treatment time with or without ultraviolet B irradiation (up to 8 weeks of treatment) with ( ⁇ ) UVB + acetone, ( ⁇ ) UVB + adapalene, M) UVB + hydroquinone, (•) UVB + hydroquinone + adapalene, (D) skin not irradiated + acetone, ( ⁇ ) skin not irradiated + adapalene, (o) skin not irradiated + hydroquinone, (V) skin not irradiated + hydroquinone + adapalene.
  • Figure 2 represents the scores for pigmentation on the tail at the end of the study (D57) with (D) acetone
  • Depigmenting activity Hydroquinone alone at 3% induces a depigmentation which is clinically visible from the 6th week of treatment (D43) and statistically significant at the end of the study.
  • Adapalene alone does not modify the natural pigmentation. When adapalene is combined with hydroquinone, it potentiates its depigmenting activity.
  • Anti-pigmenting activity In the animals irradiated and treated concomitantly, hydroquinone shows an anti- pigmenting effect at the 6th and at the 7th week (D50) , which becomes less marked at the end of the study. On the other hand, the adapalene + hydroquinone combination inhibits the pigmentation induced by UVB irradiation as soon as it appears and until the end of the study, where the difference is statistically significant (**, p ⁇ 0.01).
  • hydroquinone + adapalene combination exhibits a strong anti-pigmenting activity and significantly inhibits the pigmentation induced by UVB irradiation as soon as it appears and until the end of the study.
  • the hydroquinone + adapalene combination exhibits a significant benefit as a depigmenting agent, with respect to hydroquinone alone .
  • Example 6 Measurement of the tolerance with respect to the combination of adapalene, an antx-pigmenting agent and an anti-inflammatory agent
  • adapalene trio hydroquinone + fluocinolone acetonide combination
  • control trio combination retinoic acid
  • tretinoin hydroquinone + fluocinolone acetonide
  • the treatment is carried out 5 days a week for 4 weeks.
  • the animals are irradiated 3 times a week for 4 weeks (Monday, Wednesday, Friday) at the dose of 90 mJ/cm 2 of UVB.
  • the inflammation (erythema and squamae) is evaluated once a week before irradiation by means of a score on a scale of 0 to 4.
  • the scores are divided up as follows:
  • Figure 3 presents the overall clinical score for inflammation on the tail at the end of the 4 weeks of study after application either of the vehicle (A) , or of the adapalene trio ( ' BBl) , or of the control trio ⁇ ) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a depigmenting composition for the skin, comprising, in a physiologically acceptable medium, adapalene, at least one depigmenting agent and at least one anti- inflammatory agent, and to its pharmaceutical or cosmetic use.

Description

DEPIGMENTING COMPOSITION FOR THE SKIN, COMPRISING
ADAPALENE, AT LEAST ONE DEPIGMENTING AGENT AND AT LEAST
ONE ANTI-INFLAMMATORY AGENT
The invention relates to a depigmenting composition for the skin, comprising, in a physiologically acceptable medium, adapalene (6- [3- (1-adamantyl) -4-methoxyphenyl] - 2-naphthanoic acid) , at least one depigmenting agent and at least one anti-inflammatory agent, and to its pharmaceutical or cosmetic use.
A.M. Kligman describes, in US Patent 3,856,934, a depigmenting composition comprising hydroquinone, reti- noic acid and a corticosteroid. This type of combination allows good depigmentation of the skin but causes substantial adverse effects such as irritation and itching.
Retinoic acid (tretinoin) is known to have, on its own, a skin depigmenting activity (Guevara I.A. and Pandya A. G. Int. J. Dermatol. 40, 210-215 (2001)). In addition, tests carried out on the tail of a mouse not irradiated with UVB radiation for six weeks show that tretinoin, used at 0.01% or 0.03%, induces depigmentation of the tail which begins from the first week of treatment and progresses to reach a clear depigmentation at 6 weeks. In mice which are irradiated with UVB radiation and treated, the dose of 0.03% is capable of inhibiting the induction of pigmentation by UVB radiation, whereas the lower dose has no effect. Tretinoin is therefore a depigmenting agent on its own. On the other hand, under the same experimental conditions, adapalene has no depigmenting activity, as is shown in Example 5 hereinafter. Due to its lack of depigmenting activity in particular, nothing therefore encouraged those skilled in the art to combine it with a depigmenting agent in a depigmenting composition possibly containing an anti-inflammatory agent. However, the Applicant has discovered, surprisingly, that the combination of adapalene, a depigmenting agent and an anti-inflammatory agent makes it possible to obtain a much more rapid depigmenting response than that obtained with the depigmenting agent alone.
The Applicant has also discovered, surprisingly, that good tolerance of the skin is obtained with the combination of adapalene, a depigmenting agent and an anti-inflammatory agent, at the same time keeping a considerable depigmenting activity.
The invention therefore relates to a depigmenting composition for the skin, comprising, in a physiologically acceptable medium, adapalene, at least one depigmenting agent distinct from adapalene, and at least one anti-inflammatory agent distinct from adapalene. The composition according to the invention therefore comprises at least three different active ingredients .
The term "physiologically acceptable medium" is intended to mean a medium which is compatible with the skin, the mucous membranes and/or the integuments.
The term "depigmenting agent" is intended to mean any active agent having skin-depigmenting activity. This activity makes it possible to decrease the pigmentation of the skin that already exists and also to prevent any additional pigmentation above the natural pigmentation.
By way of non-limiting example of a depigmenting agent, mention may be made of phenolic derivatives, such as hydroquinone, hydroquinone monoethyl ether, hydro- quinone monobenzyl ether or 4-hydroxyanisole, kojic acid and its derivatives, azelaic acid and its derivatives, linoleic acid, resorcinol and its derivatives, ellagic acid, hydroxy acids such as glycolic acid, ascorbic acid, zinc peroxide, and mercury chloride.
In particular, the depigmenting composition for the skin may comprise, as depigmenting agent, a phenolic derivative, in particular hydroguinone .
The invention also relates to a depigmenting composition for the skin, comprising, in a physiologically acceptable medium, adapalene, at least one depigmenting agent distinct from adapalene and at least one anti-inflammatory agent distinct from adapalene.
To give an order of magnitude, the composition according to the invention advantageously comprises between 0.0001% and 20% by weight of adapalene relative to the total weight of the composition, and between 0.0001% and 20% by weight of depigmenting agent relative to the total weight of the composition, and preferably, respectively, between 0.001% and 10% by weight of adapalene relative to the total weight of the composition, and between 0.025% and 5% by weight of depigmenting agent relative to the total weight of the composition.
The composition comprises at least one steroidal or non-steroidal anti-inflammatory agent in preferential concentrations ranging from 0.001% to 20.00% by weight relative to the total weight of the composition.
Among steroidal anti-inflammatory agents, mention may be made, by way of non-limiting example, of clobetasone butyrate, clobetasol propionate, clobetasol dipropio- nate, hydrocortisone, cortisone, prednisolone, miconazole, prednisone, triamcinolone acetonide, methyl- prednisolone, fluometholone, fluocinolone acetonide, desonide, betamethasone, dexamethasone, or mixtures thereof . Among non-steroidal anti-inflammatory agents, mention may be made, by way of non-limiting example, of indole derivatives, arylcarboxylic derivatives such as ibu- profen, oxicams, pyrazole compounds, salicylic acid and selective COX-2 inhibitors.
In particular, the depigmenting composition for the skin may comprise fluocinolone acetonide as antiinflammatory agent .
The composition may also comprise any additive normally used in the cosmetics or pharmaceutical field, such as sequestering agents, antioxidants, sunscreens, preserving agents, fillers, electrolytes, humectants, dyes, common inorganic or organic bases or acids, fragrances, essential oils, cosmetic active agents, moisturizers, vitamins, essential fatty acids, sphingolipids, self- tanning compounds, and skin calmative and protective agents such as allantoin. Of course, those skilled in the art will take care to select this or these optional additional compound (s), and/or the amount thereof, such that the advantageous properties of the composition according to the invention are not, or are not substantially, adversely affected.
These additives may be present in the composition in a proportion of from 0.001% to 20% by weight relative to the total weight of the composition.
As examples of sequestering agents, mention may be made of: ethylenediaminetetraacetic acid (EDTA), and also derivatives or salts thereof, dihydroxyethylglycine, citric acid and tartaric acid.
As examples of preserving agents, mention may be made of benzalkonium chloride, phenoxyethanol , benzyl alcohol, diazolidinylurea and parabens .
As examples of humectants, mention may be made of: glycerol and sorbitol .
A subject of the present invention is also the composition according to the invention as described above, as a medicament.
The invention also relates to the use of the composition according to the invention as described above, in the pharmaceutical and cosmetics field.
The compositions of the invention are particularly- suitable for the treatment and prevention of hyperpig- mentary disorders such as melasma, chloasma, lenti- gines, senile lentigo, freckles, post-inflammatory hyperpigmentations due to an abrasion, a burn, a scar, a dermatosis, a contact allergy; naevi, hyperpigmentations with genetic determinism, hyperpigmentations of metabolic or drug-related origin, melanomas or any other hyperpigmentary lesions .
The compositions according to the invention also find application in the cosmetics field, in particular in protection against the harmful effects of the sun, for preventing and/or for combating photo-induced or chronological ageing of the skin and of the integuments .
The examples of formulations below make it possible to illustrate the compositions according to the invention, without, however, limiting the scope thereof. Examples illustrating the depigmenting activity of the various compositions according to the invention are also described.
In the compositions hereinafter, the proportions of the various constituents are expressed as a percentage by weight relative to the total weight of the composition. Example 1
This composition should be applied once a day until complete depigmentation is obtained, for the treatment of chloasma.
Example 2 :
This composition should be applied twice a day until complete depigmentation is obtained, for the treatment of lentigines.
Example 3 :
This composition should be- applied once a day until complete depigmentation is obtained, for the treatment of melasma.
Example 4 :
This composition should be applied twice a day until complete depigmentation is obtained, for the treatment of lentigines.
Example 5 - Measurement of the depigmenting activity of the combination of adapalene and a depigmenting agent
The evaluation of the depigmenting and/or anti-pigment- ing activity of 3% hydroquinone and of 0.1% adapalene, alone or in combination for 8 weeks, is carried out on the tail of an SKH:HR2 mouse irradiated with ultraviolet B radiation, or not irradiated. The tail of the SKH-.HR2 mouse is naturally pigmented and this pigmentation increases under the effect of repeated UVB irradiation. The depigmenting activity is measured on the natural pigmentation after application of the test product to the tail of non-irradiated animals. The anti-pigmenting activity is measured by the inhibition of the induction of the UV-induced pigmentation: the test product is applied to the tail of UVB-irradiated animals .
The treatment is carried out 5 days a week for 8 weeks. 20 μl of test product diluted in acetone are applied to the tail with a gap between applications: the hydroquinone is applied in the morning and the adapalene 4 h later. On the days of irradiation, the treatment is applied after irradiation.
The animals are irradiated 3 times a week for 8 weeks (Monday, Wednesday, Friday) at the dose of 90 mJ/cm2 of UVB.
The pigmentation is evaluated once a week before irradiation, by means of a score on a scale of 0 to 4. The scores are divided up as follows:
Depigmentation scale: scores -1 to -4.
0 : natural pigmentation
-1: slight depigmentation
-2 : moderate depigmentation
-3 : marked depigmentation
-4 : complete depigmentation
Pigmentation scale-, scores 1 to 4 1: slight pigmentation 2 : moderate pigmentation 3 : marked pigmentation 4 : strong pigmentation
The results are given in Figures 1 and 2.
Figure 1 represents the kinetics of the mouse tail skin pigmentation scores as a function of treatment time with or without ultraviolet B irradiation (up to 8 weeks of treatment) with (♦) UVB + acetone, (►) UVB + adapalene, M) UVB + hydroquinone, (•) UVB + hydroquinone + adapalene, (D) skin not irradiated + acetone, (Δ) skin not irradiated + adapalene, (o) skin not irradiated + hydroquinone, (V) skin not irradiated + hydroquinone + adapalene.
Figure 2 represents the scores for pigmentation on the tail at the end of the study (D57) with (D) acetone,
(S3,) hydroquinone, [W) adapalene, (Ji) adapalene + hydro- quinone with or without ultraviolet B irradiation.
Depigmenting activity: Hydroquinone alone at 3% induces a depigmentation which is clinically visible from the 6th week of treatment (D43) and statistically significant at the end of the study. Adapalene alone does not modify the natural pigmentation. When adapalene is combined with hydroquinone, it potentiates its depigmenting activity.
Anti-pigmenting activity: In the animals irradiated and treated concomitantly, hydroquinone shows an anti- pigmenting effect at the 6th and at the 7th week (D50) , which becomes less marked at the end of the study. On the other hand, the adapalene + hydroquinone combination inhibits the pigmentation induced by UVB irradiation as soon as it appears and until the end of the study, where the difference is statistically significant (**, p < 0.01).
Conclusion
After 8 weeks of topical treatment on the tail of an SKH-.HR2 mouse, it is noted that the hydroquinone + adapalene combination exhibits a strong anti-pigmenting activity and significantly inhibits the pigmentation induced by UVB irradiation as soon as it appears and until the end of the study. The hydroquinone + adapalene combination exhibits a significant benefit as a depigmenting agent, with respect to hydroquinone alone .
Example 6 - Measurement of the tolerance with respect to the combination of adapalene, an antx-pigmenting agent and an anti-inflammatory agent The evaluation of the tolerance with respect to the adapalene + hydroquinone + fluocinolone acetonide combination ("adapalene trio") formulated in a cream, in comparison with that obtained with the combination retinoic acid (tretinoin) + hydroquinone + fluocinolone acetonide ("control trio") in the same vehicle for 4 weeks, is carried out on the tail of an SKH:HR2 mouse which is UVB-irradiated or not irradiated. The same measurements are also realized on the vehicle alone and without active agents. The tolerance after application of the test product is measured with ultraviolet B (UBV) -irradiation and without ultraviolet B- irradiation.
The treatment is carried out 5 days a week for 4 weeks.
20 μl of formulated test product are applied to the tail. On the days of irradiation, the treatment is applied after irradiation.
The animals are irradiated 3 times a week for 4 weeks (Monday, Wednesday, Friday) at the dose of 90 mJ/cm2 of UVB.
The inflammation (erythema and squamae) is evaluated once a week before irradiation by means of a score on a scale of 0 to 4. The scores are divided up as follows:
0 : normal skin without inflammation
1: slight inflammation
2 : moderate inflammation
3 : marked inflammation 4: severe inflammation.
The results are given in Figure 3.
Figure 3 presents the overall clinical score for inflammation on the tail at the end of the 4 weeks of study after application either of the vehicle (A) , or of the adapalene trio ('BBl) , or of the control trio {β) . Conclusion
The signs of inflammation are clearly less marked with the adapalene trio than with the control trio.
The comparative study of adapalene trio versus control trio for 4 weeks on the tail in mice shows that the adapalene trio exhibits much better tolerance than the control trio.

Claims

Claims
1. Depigmenting composition for the skin, comprising adapalene, at least one depigmenting agent distinct from adapalene and at least one anti-inflammatory agent distinct from adapalene, in a physiologically acceptable vehicle.
2. Composition according to Claim 1, characterized in that the depigmenting agent is a phenolic derivative.
3. Composition according to either one of Claims 1 and 2, characterized in that the depigmenting agent is hydroquinone .
4. Composition according to any one of Claims 1 to 3 , characterized in that the anti-inflammatory agent is fluocinolone acetonide .
5. Composition according to any one of Claims 1 to 4 , as a medicament .
6. Use of a composition according to any one of Claims 1 to 4, in the manufacture of a pharmaceutical preparation for use in the prevention or treatment of hyperpigmentary disorders such as melasma, chloasma, lentigines, freckles, post-inflammatory hyperpigmenta- tions due to an abrasion, a burn, a scar, a dermatosis, a contact allergy, naevi, hyperpigmentations with a genetic determinism, hyperpigmentations of metabolic or drug-related origin, melanomas or any other hyperpigmentary lesions .
7. Use according to Claim 6, in the manufacture of a pharmaceutical preparation for use in the prevention or treatment of melasma.
8. Cosmetic use of a composition according to any one of Claims 1 to 4, for protection against harmful effects of the sun, for preventing and/or for combating photo-induced or chronological ageing of the skin and of the integuments.
EP06842260A 2005-09-02 2006-08-31 Depigmenting composition for the skin, comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent Withdrawn EP1926484A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0509003A FR2890314B1 (en) 2005-09-02 2005-09-02 SKIN POWDER COMPOSITION COMPRISING ADAPALENE AT LEAST ONE DEPIGMENTING AGENT AND AT LEAST ONE ANTI-INFLAMMATORY AGENT
US71776705P 2005-09-19 2005-09-19
PCT/IB2006/003725 WO2007052157A2 (en) 2005-09-02 2006-08-31 Depigmenting composition for the skin, comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent

Publications (1)

Publication Number Publication Date
EP1926484A2 true EP1926484A2 (en) 2008-06-04

Family

ID=38006259

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06842260A Withdrawn EP1926484A2 (en) 2005-09-02 2006-08-31 Depigmenting composition for the skin, comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent

Country Status (3)

Country Link
EP (1) EP1926484A2 (en)
CA (1) CA2616915A1 (en)
WO (1) WO2007052157A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856934A (en) * 1970-06-24 1974-12-24 A Kligman Skin depigmentation
US6358541B1 (en) * 2000-05-03 2002-03-19 David S. Goodman Topical preparation for the treatment of hair loss
FR2833841B1 (en) * 2001-12-21 2005-07-22 Galderma Res & Dev GEL COMPRISING AT LEAST ONE RETINOID AND BENZOYL PEROXIDE
MXPA05002064A (en) * 2002-09-05 2005-06-08 Galderma Res & Dev Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007052157A2 *

Also Published As

Publication number Publication date
WO2007052157A3 (en) 2007-10-04
CA2616915A1 (en) 2007-05-10
WO2007052157A2 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
US3856934A (en) Skin depigmentation
Bandyopadhyay Topical treatment of melasma
US9333172B2 (en) Topical skin care composition
JPH07501541A (en) Uses of salicylic acid to control skin wrinkles and/or skin atrophy
JP4217740B2 (en) Composition comprising amidine and alkane polyol
JP4662769B2 (en) Depigmenting composition for skin comprising adapalene and at least one depigmenting agent
MX2010012753A (en) Anhydrous depigmenting compositions comprising, within the fatty phase, a solubilized phenolic derivative and a retinoid.
US20100124538A1 (en) Topical application of fluocinolone acetonide for depigmentation of the skin
WO2009063491A2 (en) Topical compositions for skincare
EP1926484A2 (en) Depigmenting composition for the skin, comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent
CA2022917C (en) Synergistic skin depigmentation composition
US20080219936A1 (en) Skin depigmenting compositions comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent
WO2007068701A1 (en) Aqueous-alcoholic depigmenting gel
Mashhood Treatment of hyperpigmentation disorders
JP2009519304A (en) Use of a dermatological composition comprising a combination of hydroquinone, fluocinolone acetonide, and tretinoin for treating hyperpigmentation of the skin following psoriasis or eczema
Westerhof et al. Bleaching agents
EP1813312A2 (en) Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent
OA12083A (en) A method of treating and lightening hyperpigmentation in black skin with a retinoid.
Liang et al. Growth Suppression of Hamster Flank Organs by Topical Application ofy-Linolenic and Other Fatty

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080404

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20100209

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20121217